SLC5A2 and dementia: A meta-analysis by Youn et al. (2024) included 12 studies with a total of 45,089 participants and reported a pooled hazard ratio of 0.68 (95% CI: 0.50–0.92) for dementia incidence among SGLT-2 inhibitor users [55].